Sort by
Search results
Emicizumab Calibrator
Calibration of a modified one-stage FVIII activity assay for determination of active emicizumab concentration from a clot time measurement performed on an automated coagulation analyzer.
Emicizumab Controls
Quality control of a modified one-stage FVIII activity assay for determination of active emicizumab concentration from a clot time measurement performed on an automated coagulation analyzer.
Epinephrine
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g., myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.
FIBRIPHEN 1
Measurement of fibrinogen in plasma. Detection of low fibrinogen concentrations. Detection of elevated fibrinogen concentrations (> 4g/L): In clinical situations associated with inflammation Risk factor for cardiovascular disease and thrombosis Hypofibrinogenemia, mainly associated with severe liver disease, and excessive consumption of fibrinogen (DIC, hyperfibrinolysis). Numerous variants of fibrinogen described, associated to asymptomatic cases, or to cases with bleeding and/or thrombosis.
FIBRIPHEN 2
Measurement of fibrinogen in plasma. Detection of low fibrinogen concentrations. Detection of elevated fibrinogen concentrations (> 4g/L): In clinical situations associated with inflammation Risk factor for cardiovascular disease and thrombosis Hypofibrinogenemia, mainly associated with severe liver disease, and excessive consumption of fibrinogen (DIC, hyperfibrinolysis). Numerous variants of fibrinogen described, associated to asymptomatic cases, or to cases with bleeding and/or thrombosis.
FIBRIPHEN 5
Measurement of fibrinogen in plasma. Detection of low fibrinogen concentrations. Detection of elevated fibrinogen concentrations (> 4g/L): In clinical situations associated with inflammation Risk factor for cardiovascular disease and thrombosis Hypofibrinogenemia, mainly associated with severe liver disease, and excessive consumption of fibrinogen (DIC, hyperfibrinolysis). Numerous variants of fibrinogen described, associated to asymptomatic cases, or to cases with bleeding and/or thrombosis.
FIBRIPHEN™ LRT
Clotting method for quantitative determination of fibrinogen (Clauss method)
FII Inhibitor Plasma (1) mild (1-10 BU/ml), frozen
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.
FIX Inhibitor Plasma (1) mild (1-10 BU/ml), frozen
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.
FIX Inhibitor Plasma (1) mild (1-10 BU/ml), lyophilized
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.